New results from study of Oncotype DX diagnostics system in breast cancer risk- Genomic Health

Genomic Health announced new 5-year clinical outcomes results from a large PlanB study of the Oncotype DX breast cancer diagnostics system. The study, conducted by the West German Study Group, showed that 94% of early-stage breast cancer patients with Oncotype DX Recurrence Score results of 11 or less, who were treated with hormonal therapy alone, were disease-free 5 years after diagnosis. In women with Recurrence Score results of 11 or less who were treated with hormonal therapy alone, 5-year disease free survival (DFS) was estimated as 94%. Patients with Recurrence Score results of 12 to 25 who were treated with adjuvant chemotherapy also had 5-year DFS rates of 94%, while in patients with Recurrence Score results above 25 who had also received chemotherapy, 5-year DFS rates were 84%.

These new PlanB study results with 5-year outcomes provide information beyond the 3-year outcomes published recently in the Journal of Clinical Oncology. Results were announced in an oral presentation at the 10th European Breast Cancer Conference.